VBLT News and Press, Vascular Biogenics Ltd. From 03/28/19

Vascular Biogenics Ltd. (VBLT) Q4 2018 Results Conference Call March 28, 2019 08:30 AM ET Company Participants Michael Wood - LifeSci Advisors Dror Harats - CEO Amos Ron - CFO Erez Feige - VP of Business Operations Conference Call Participants Swayampakula Ramakanth - H.C...

VBL Therapeutics (NASDAQ: VBLT ): FY GAAP EPS of -$0.62 beats by $0.07. More news on: Vascular Biogenics Ltd., Earnings news and commentary, Healthcare stocks news, , Read more ...

Development of Phase 3 product candidate VB-111 continues in ovarian cancer toward interim analysis at year-end 2019 and expands through investigator-sponsored trials in rGBM and colon cancer Signed strategic agreement for VB-201 for veterinary use; potential payments to VBL may exceed...

TEL AVIV, Israel, March 25, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ), today announces that the Company will present data on its Phase 3 drug candidate VB-111, at the 2019 American Association for Cancer Research (AACR) Annual Meeting , to be held March 29 - April 3, 201...

Altimmune (NASDAQ: ALT ) +44%  on positive NasoVAX data . More news on: Altimmune, Inc., Vaxart, Inc., Cellectar Biosciences, Inc., Stocks on the move, Read more ...

VBL Therapeutics (NASDAQ: VBLT ) is up  11%  premarket on modestly higher volume on the heels of new data on anti-cancer gene therapy ofranergene obadenovec (VB-111). The results were presented at the SGO Annual Meeting on Women's Cancer in Honolulu. More news on: Vascular Biog...

TEL AVIV, Israel, March 19, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ), today announced the presentation of human data indicating that the viral anti-cancer investigational therapy VB-111 has potential to stimulate the immune system to induce a strong and durable respo...

TEL AVIV, Israel, March 14, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audi...

TEL AVIV, Israel, March 11, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announces that the company will present data on its Phase...

TEL AVIV, Israel, Feb. 26, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ), (the “Company”) today announced new data implicating the potential of its VB-600 platform of antibodies targeting MOSPD2 (motile sperm domain-containing protein 2) for treatment of var...